Venous Thromboembolism (vte)

The concept of venous thromboembolism (VTE) is such that, it is associated with the manifestation of both Deep vein thrombosis (DVT) and pulmonary embolism (PE) .

VENOUS THROMBOEMBOLISM (VTE)

CHARACTERISTICS  It

is composed of a combination of factors from the Virchow’s triad.

 It is located in the Venous

sinusoids of muscles and valves in veins.  It is composed of mainly

fibrin.  It is utilized for the purpose

of treating anticoagulants.

THE PRACTICAL ESSENTIALS  Venous thromboembolism (VTE) is basically associated with two

inter-related conditions forming a part of the same spectrum, pulmonary embolism and deep vein thrombosis (DVT) (Ambrosino et al., 2017).  The diagnosis must be taken into consideration by the confirmation of

objective testing.  Patients suffering from deep vein thrombosis (DVT) is usually treated

by considering them as an outpatient.

Anatomy  It is a major preventable cause of mobility and

mortality.  It occurs in areas of decreased or mechanical blood flows.  As a result of blood flows, the tension of oxygen declines.  The diagnosis and treatment of the lower extremity deep venous thrombosis is dependent upon the anatomic location.

Continued  Deep Venous Thrombosis is associated with more amount

  



of blood clots in the form of deep vein in the body. The common area for Deep Venous Thrombosis is in the lower limbs. In the upper extremity, Deep Venous Thrombosis are less common. Blood work may be done in initial stage however; a test called D-dimer, which is used for detecting clotting activity. In case of DVT is important to perform an ultrasound of the leg.

Physiology  It tends to occur in areas of decreased mechanical altered

flow of blood which are adjacent to the flow of veins.  These valves helps in the promotion of deceased blood flow.  Most of the time of ventilation perfusion lungs scan is also performed.  Mention can be made regarding the fact that, both the tests are useful as it helps to identify the intravenous dyes in the arteries of the lung by looking at the blockage of clot.

Continued  The objective of the therapy of VTE is regarding the

prevention of the extension of thrombus, PE for the purpose of relieving the symptoms within a short period of time.  LMWH has changed the nature of the landscape of the treatments in case of both DVT and PE by providing home remedies and with an alternative long-term anticoagulant in case of that population in whom warfarin is not effective and contraindicated.

Pathophysiology  The clinical condition of DVT is such that, it is associated

 





with both the cardinal signs and symptoms . In this regard, a number of factors are associated with high risk factors. The nature of DVT is such that, the thrombi develops due to hyper coagulation and stasis surrounding the valve sinuses. In the initial stage, the majority of the thrombi starts in the calf. These blood clots are made of fibrin and red blood cells.

Continued  The flow of blood and the ability of a clotting help a

human being to stay alive. However, in some cases, blood clotting can be a serious issue and leads to a dangerous situation.  It is associated with asymptomatic or cause pain by swelling an extremity and pulmonary embolism.  In case of duplex ultra sonography, DVT is detected and the detection of negative results helps in the exlusion of DVT.

Incidence above the age of 70 years  The incidence among adults is much more.  However, in case of adults aged above 70 years, the

condition becomes more serious as a result of associated risks.  These risks often lead to low eyesight and issues in walking.  In case of patients above 70 years, DVT is associated with long term complications including venous insufficiency with or without the post phlebitic syndrome.

Continued  In older patients, for the purpose of treating DVT, surgical

operations are required.  It creates significant impact upon both morbidity and mortality in elderly patients above the age of 70.  The risk factors includes surgery and immobilization.  Venous thrombosis and its consequences are much more serious in case of patients above 70 because; it is associated with lower levels of anticoagulant proteins, including protein C and antithrombin.

ASSOCIATED RISKS The risks of venous thromboembolism (vte) are associated with various factors including Age.  Major surgeries.  Previous trauma.  Limb paralysis.  Malignancy.

Clinical Problems  The clinical problems are associated with various factors .  It is worth mentioning that, both Deep venous thrombosis (DVT) and

pulmonary embolism (PE) in collaboration has been comprising the spectrum of the venous thromboembolic disease (VTE) (Cohen et al., 2017).  In this regard, mention can be made regarding the fact that, from the very

beginning, the venous thromboembolic disease (VTE), has been a major cause of increasing rate of hospitalization for both adults and children .  As a result of this, the major surgeries including the procedure of

childbirth becomes very complicated causing (Ay, Pabinger & Cohen, 2017).  It is often accompanied with significant death risks and long term

syndromes involving postphlebitic syndrome and core pulmonale.

Historical representation  Historically, before the advent and widespread of heparin, it was observed

that more than 20% of the patients suffering from DVT died.  It is noteworthy to mention here that, these clinical contributions were not

adequate for the diagnosis of venous thromboembolic disease (VTE).  This is due to the reason that, the existing modalities also plays significant

role however; the nature of their characteristics are such that, it needs to be evaluated and identified and thereafter incorporate them into costeffective diagnostic strategies (Connors, 2017).  It is evident that, the historical management of heparinization has

increased the rates of hospitalization.  With the utilization of LMWH , the clinical methods have become

standard and the complications associated with anti-coagulation will reduce.  However, the patients who are not capable of receiving anticoagulants and

others who cannot receive anticoagulants at all complicates the successful management of their venous thromboembolic disease (VTE) (Fang et al., 2017).

Diagnosis of VENOUS THROMBOEMBOLISM (VTE)  From

the very inception, the diagnosis of both venous thromboembolic disease (VTE) AND DVT has been sharing common principles which includes the development of the estimation of clinical likelihood.

 These estimates are compared efficiently in regard to the underlying

probabilities by developing them independently by way of laboratory test, research and studies (Ferroni et al., 2017).  In this context, it can be stated that, the nature of the operational

procedures are such that, it differs from both DVT and VTE. This is due to the reason, the diagnosis of both DVT and VTE are mentioned separately.

Primary risk factors

The primary risk factors in case of VTE includes From the very beginning, the pathogenesis of both DVT and VTE are

based upon the concept of Virchow’s trial.  The limitation of blood flow.  Endothelial injury.  Hypercoaguable state.

It is noteworthy to mention here that, each of these risk factors are associated with the development of venous thromboembolic disease (VTE) which is either hereditary or acquired (Gibson et al., 2017).

Treatment of VTE The treatment of VTE is associated with various clinical factors. It is worth mentioning that, anticoagulation is identified as the most common form of treatment used for treating the patients of VTE. In this regard, it is pertinent to mention here that, thrombosis of superficial veins and those which are distal towards the brachial vein does not require active treatment with anticoagulation. Inferior vena cava filter is another method of treatment in which the filter is placed after the anticoagulation has failed to provide the ultimate results (Heit et al., 2017).The method of aggressive clot removal is also taken into consideration in some cases. It is associated with the process of thrombolytic therapy in case of DVT which is performed in case of massive conditions. It serves to be appropriate in cases associated with DVT along with thoracic outlet compression. The process of secondary prevention and prophylaxis is also used to treat VTE (Khorana et al., 2017).

Anticoagulation for VTE  The setting of anticoagulation treatment is related to both outpatient and

impatient. However, mention can be made regarding the fact that, the outpatient treatment has various advantages.  These advantages are associated with low cost by providing high level of

treatment to the patients for the purpose of easing their pain.  On the other hand, the impatient treatment involves active monitoring and

immediate responses to certain clinical changes.  It is noteworthy to mention here that, from time to time, a substantial

number of patients suffering from VTE (Laliberté et al., 2018).

are treated as outpatients

 However, these treatments are only accessible to limited number of

patients having low risk. In few cases, the outpatient treatment can be taken into consideration.

Anticoagulation and pregnancy  The condition of VTE and its association with pregnancy is not

known to all. However, it is believed that, the condition is associated with much serious consequences and greater substantiality which is much more serious than that of nonpregnant women. I  t is worthwhile to mention here that, only two-thirds of DVT can be observed before delivery and these incidences are basically distributed fairly throughout the pregnancy.  It can be observed that, a percentage of 40-60% of PE can be observed during 5-6 weeks after the delivery.  It is pertinent to mention here that, the predilection of DVT can be observed in the left leg during pregnancy because, of underlying compression effects on the left iliac vein.

Right time to inform the patient  It is important to inform the patient accordingly regarding their serious

condition.  The condition of Venous thromboembolism is associated with serious

issues which are caused as a result of blood clot n the deep venous system.  Therefore, it is important to maintain balance between blood clotting

in order to obstruct the continuous flow of blood.  Any kind of blood thinner both orally or by injection should be taken

as prescribed by the physician.  In case of any failure to comply with the instructions provided by the

physician, can increase further risk.

Measures of Clinical Performance

It is noteworthy to mention here that, most of the National Programs have developed clinical performance measures for the purpose of taking care of conditions related to hypertension. These centers include Centers for Medicare & Medicaid Services  Quality measures for Accountable Care Organizations (ACO)  Physician Quality Reporting Measures for Group Practice Reporting

Option (GPRO)  Use of certified Electronic Health Record technology (MU).

Clinical performance Measures for VTE The clinical performance measures for VTE can be categorized as The programs having relevant measures

can be considered to have created serious impact upon the community. However, certain specifications may vary in regard to the inclusion and exclusion of population.  Monthly INR are received by the health

beneficiaries from time to time.

Therapies other than anticoagulation  The therapies other than anticoagulation include platelet monitoring

by using impatient process. Mention can be made regarding the fact that, a high percentage of patients diagnosed with VTE have received intravenous UFH therapy as a part of their treatment (Raskob et al., 2018). In this way, their platelet counts are monitored in regard to the defined parameters including nomogram or protocol.  The other therapy is the anticoagulation overlap therapy (inpatient).

In this case, the percentage of people diagnosed with VTE receives overlap of parenteral (intravenous or subcutaneous) anticoagulation and warfarin as a part of their treatment. In case of patients receiving such treatment for a time period less than five days are accessible to parenteral anticoagulation therapy

VTE discharge instructions

The percentage of patients diagnosed with VTE are discharged from clinical observations after issuing a discharge instruction form in written duly signed by the higher authority of such institution by addressing these criteria Compliance procedures.  Dietary advices.  Monitoring and regular follow-ups.  Relevant information about certain drugs and their adverse effect .  Negative trials are sometimes sought.

Conclusion

In the conclusion, it can be stated that, the condition of venous thromboembolism (VTE) is a serious condition and is associated with various medications and treatments. However, an under-observed patient gains better results under constant care. Therefore, it can be concluded that, it is important to comply with the underlying factors for the purpose of enhancing reliability and accuracy.

References Ambrosino, P., Tarantino, L., Di Minno, G., Paternoster, M., Graziano, V., Petitto, M., ... & Di Minno, M. N. D. (2017). The risk of venous thromboembolism in patients with cirrhosis. Thrombosis and haemostasis, 26(01), 139-148. Ay, C., Pabinger, I., & Cohen, A. T. (2017). Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thrombosis and haemostasis, 117(02), 219-230. Cohen, A. T., Katholing, A., Rietbrock, S., Bamber, L., & Martinez, C. (2017). Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. Thrombosis and haemostasis, 26(01), 57-65. Connors, J. M. (2017). Thrombophilia testing and venous thrombosis. New England Journal of Medicine, 377(12), 1177-1187. Fang, M. C., Fan, D., Sung, S. H., Witt, D. M., Schmelzer, J. R., Steinhubl, S. R., ... & Go, A. S. (2017). Validity of Using Inpatient and Outpatient Administrative Codes to Identify Acute Venous Thromboembolism: The CVRN VTE Study. Medical care, 55(12), e137-e143. Ferroni, P., Zanzotto, F. M., Scarpato, N., Riondino, S., Nanni, U., Roselli, M., & Guadagni, F. (2017). Risk assessment for venous thromboembolism in chemotherapy-treated ambulatory cancer patients: a machine learning approach. Medical Decision Making, 37(2), 234-242. Gibson, C. M., Halaby, R., Korjian, S., Daaboul, Y., Arbetter, D. F., Yee, M. K., ... & Bandman, O. (2017). The safety and efficacy of full-versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. American heart journal, 185, 93-100.

References Heit, J. A., Ashrani, A. A., Crusan, D. J., McBane, R. D., Petterson, T. M., & Bailey, K. R. (2017). Reasons for the persistent incidence of venous thromboembolism. Thrombosis and haemostasis, 117(02), 390-400. Khorana, A. A., Francis, C. W., Kuderer, N. M., Carrier, M., Ortel, T. L., Wun, T., ... & Baran, A. (2017). Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thrombosis research, 151, 89-95. Laliberté, F., Dea, K., Duh, M. S., Kahler, K. H., Rolli, M., & Lefebvre, P. (2018). Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause, 25(11), 1297-1305. Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., ... & Meyer, G. (2018). Edoxaban for the treatment of cancer-associated venous thromboembolism. New England Journal of Medicine, 378(7), 615-624. Trujillo-Santos, J., Di Micco, P., Dentali, F., Douketis, J., Díaz-Peromingo, J. A., Núñez, M. J., ... & RIETE Investigators. (2017). Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thrombosis and haemostasis, 117(02), 382-389. Van Es, N., Franke, V. F., Middeldorp, S., Wilmink, J. W., & Büller, H. R. (2017). The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer. Thrombosis research, 150, 30-32. Young, A. M., Marshall, A., Thirlwall, J., Chapman, O., Lokare, A., Hill, C., ... & MacCallum, P. (2018). Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). Journal of Clinical Oncology, 36(20).

THANK YOU